Lupin's subsidiary to set up plant in Japan
New Delhi: Drug major Lupin said its wholly-owned Japanese subsidiary, Kyowa, plans to set up a manufacturing plant at Tottori, Japan as part of expansion plans in the country.
"In order to meet the rapidly growing demand of generics, the Kyowa board has proposed the setting-up of a two billion tablets capacity plant at Tottori, Japan which would be designed to efficiently handle mass volume products and provide flexibility in allowing easy future expansion," Lupin Ltd said in a regulatory filing.
Kyowa Pharmaceutical Industry Co is a wholly-owned subsidiary of the the Mumbai-based firm. It has a manufacturing facility at Sanda, Japan.
The drug maker, however, did not disclose financial details regarding the proposed plant.
"In order to meet the rapidly growing demand of generics, the Kyowa board has proposed the setting-up of a two billion tablets capacity plant at Tottori, Japan which would be designed to efficiently handle mass volume products and provide flexibility in allowing easy future expansion," Lupin Ltd said in a regulatory filing.
Kyowa Pharmaceutical Industry Co is a wholly-owned subsidiary of the the Mumbai-based firm. It has a manufacturing facility at Sanda, Japan.
The drug maker, however, did not disclose financial details regarding the proposed plant.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd